» Articles » PMID: 16596786

Cannabinoid Mechanisms of Pain Suppression

Overview
Specialty Pharmacology
Date 2006 Apr 7
PMID 16596786
Citations 70
Authors
Affiliations
Soon will be listed here.
Abstract

A large body of literature indicates that cannabinoids suppress behavioral responses to acute and persistent noxious stimulation in animals. This review examines neuroanatomical, behavioral, and neurophysiological evidence supporting a role for cannabinoids in suppressing pain at spinal, supraspinal, and peripheral levels. Localization studies employing receptor binding and quantitative autoradiography, immunocytochemistry, and in situ hybridization are reviewed to examine the distribution of cannabinoid receptors at these levels and provide a neuroanatomical framework with which to understand the roles of endogenous cannabinoids in sensory processing. Pharmacological and transgenic approaches that have been used to study cannabinoid antinociceptive mechanisms are described. These studies provide insight into the functional roles of cannabinoid CB1 (CB1R) and CB2 (CB2R) receptor subtypes in cannabinoid antinociceptive mechanisms, as revealed in animal models of acute and persistent pain. The role of endocannabinoids and related fatty acid amides that are implicated in endogenous mechanisms for pain suppression are discussed. Human studies evaluating therapeutic potential of cannabinoid pharmacotherapies in experimental and clinical pain syndromes are evaluated. The potential of exploiting cannabinoid antinociceptive mechanisms in novel pharmacotherapies for pain is discussed.

Citing Articles

Quantification and time course of subjective psychotropic and somatic effects of tetrahydrocannabinol - a prospective, single-blind, placebo-controlled exploratory trial in healthy volunteers.

Kleine-Brueggeney M, Huber M, Theiler L, Priemer F, Greif R BMC Psychiatry. 2024; 24(1):902.

PMID: 39696071 PMC: 11654089. DOI: 10.1186/s12888-024-06338-2.


Heterosynaptic long-term potentiation of non-nociceptive synapses requires endocannabinoids, NMDARs, CamKII, and PKCζ.

Franzen A, Paulsen R, Kabeiseman E, Burrell B J Neurophysiol. 2023; 129(4):807-818.

PMID: 36883763 PMC: 10085563. DOI: 10.1152/jn.00494.2022.


Reduced Endocannabinoid Tone in Saliva of Chronic Orofacial Pain Patients.

Haviv Y, Georgiev O, Gaver-Bracha T, Hamad S, Nemirovski A, Hadar R Molecules. 2022; 27(14).

PMID: 35889535 PMC: 9322033. DOI: 10.3390/molecules27144662.


Transcriptomic Profiling in Mice With CB1 receptor Deletion in Primary Sensory Neurons Suggests New Analgesic Targets for Neuropathic Pain.

Liu Y, Jia M, Wu C, Zhang H, Chen C, Ge W Front Pharmacol. 2022; 12:781237.

PMID: 35046811 PMC: 8762320. DOI: 10.3389/fphar.2021.781237.


Evidence for Brain Region-Specific Molecular Interactions Between Cannabinoid and Orexin Receptors.

Kim H, Zagzoog A, Smolyakova A, Ezeaka U, Benko M, Holt T Front Neurosci. 2022; 15:790546.

PMID: 34992518 PMC: 8724524. DOI: 10.3389/fnins.2021.790546.